- Home
- LPTX
as 07-11-2025 2:37pm EST
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 119.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $4.79 | Next Earning Date: | 08-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Leap Therapeutics Inc. News
LPTX Breaking Stock News: Dive into LPTX Ticker-Specific Updates for Smart Investing
MT Newswires
19 days ago
Leap Therapeutics' Colorectal Cancer Study Shows Significant Benefits; Workforce Cuts Coming
PR Newswire
19 days ago
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
PR Newswire
2 months ago
Leap Therapeutics Reports First Quarter 2025 Financial Results
PR Newswire
3 months ago
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
PR Newswire
3 months ago
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer
Benzinga
4 months ago
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
MT Newswires
4 months ago
Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial
PR Newswire
4 months ago
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Compare LPTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LPTX Leap Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.